EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
SALT LAKE CITY, Dec. 28, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2017 JP Morgan Healthcare Conference at 6:00 p.m. ET on January 9, 2017, at the Westin St. Francis Hotel in San Francisco, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, GeneSight, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (908) 285-0248 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
